Royal Bank Of Canada Has Lowered Expectations for Insulet (NASDAQ:PODD) Stock Price

Insulet (NASDAQ:PODD) had its price objective reduced by analysts at Royal Bank Of Canada from $280.00 to $245.00 in a report issued on Monday,Benzinga reports. The brokerage currently has an “outperform” rating on the medical instruments supplier’s stock. Royal Bank Of Canada’s price target would indicate a potential upside of 50.70% from the stock’s previous close.

A number of other research firms have also recently issued reports on PODD. Leerink Partners cut their target price on shares of Insulet from $360.00 to $247.00 in a research note on Thursday, May 7th. Raymond James Financial set a $216.00 price target on Insulet in a research report on Monday, June 8th. TD Cowen dropped their price target on Insulet from $379.00 to $294.00 and set a “hold” rating for the company in a report on Monday, June 1st. Sanford C. Bernstein cut their price objective on Insulet from $330.00 to $200.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Finally, Wells Fargo & Company reduced their price objective on Insulet from $360.00 to $255.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. Twenty-two analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Insulet presently has a consensus rating of “Moderate Buy” and a consensus target price of $235.62.

Insulet Price Performance

Shares of PODD traded up $1.30 during trading hours on Monday, hitting $162.58. The stock had a trading volume of 205,616 shares, compared to its average volume of 1,235,544. The stock has a market capitalization of $11.26 billion, a price-to-earnings ratio of 37.89, a P/E/G ratio of 1.12 and a beta of 1.11. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. The company’s fifty day moving average is $152.93 and its two-hundred day moving average is $210.77. Insulet has a 52 week low of $138.79 and a 52 week high of $354.88.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.23. The firm had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The firm’s quarterly revenue was up 33.9% on a year-over-year basis. During the same period last year, the firm posted $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, analysts anticipate that Insulet will post 6.46 EPS for the current year.

Insider Buying and Selling at Insulet

In other Insulet news, Director Timothy C. Stonesifer acquired 2,790 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were acquired at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the acquisition, the director directly owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This represents a 44.63% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.36% of the stock is currently owned by company insiders.

Institutional Trading of Insulet

A number of institutional investors have recently bought and sold shares of PODD. Larson Financial Group LLC lifted its stake in shares of Insulet by 114.6% in the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 47 shares during the period. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Insulet during the fourth quarter worth $26,000. Elyxium Wealth LLC bought a new stake in Insulet in the fourth quarter valued at about $28,000. DV Equities LLC bought a new stake in Insulet in the fourth quarter valued at about $28,000. Finally, MV Capital Management Inc. acquired a new position in Insulet in the fourth quarter valued at about $29,000.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.